stockrow
Friday 6 November 2026
Export LFCR’s income statement to Excel — free account
Lifecore Biomedical, Inc.
LFCR Healthcare Drug Manufacturers Specialty & Generic
Lifecore Biomedical, Inc.’s revenue for fiscal 2025 (year ended May 2025) was $128.9 million, roughly unchanged from fiscal 2024.
- Revenue
- −18.6%
- EPS
- −1,665.3%
- Free cash flow
- +27,684.0%
- Total debt
- +38.4%
Quarter to September 2026, against a year earlier
6.37
0.03
−0.47%
Follow LFCR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 1.14 | 1.65 | 2.19 | |
P/FCF ratio |
— | 4.20 | 13.49 | 12.07 | |
P/Operating CF |
— | 29.66 | (90.12) | 35.85 | |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | |
EV/Sales |
— | 2.19 | 3.06 | 3.95 | |
EV/EBITDA |
— | 369.53 | 0.00 | 142.66 | |
EV/Operating CF |
— | 10.90 | 35.76 | 29.12 | |
EV/FCF |
— | 8.05 | 25.02 | 21.76 | |
Quick Ratio |
1.85 | 1.96 | 2.20 | 2.00 | |
Current Ratio |
3.49 | 3.79 | 3.87 | 3.84 | |
Net Debt/EBITDA |
0.00 | (53.76) | 33.01 | 131.36 | |
Debt/Assets |
72.29% | 65.53% | 80.62% | 97.32% | |
Debt/Equity |
4.93 | 7.11 | 11.50 | (9.97) | |
Asset Turnover |
0.00 | 0.52 | 0.51 | 0.49 | |
Operating CF/Net income |
— | (0.29) | 0.31 | (0.17) | |
Capex/Depreciation |
— | (0.48) | (0.20) | (0.38) | |
Interest Coverage |
— | (0.64) | 0.33 | (0.11) | |
Research and Development Expense of Revenue |
— | 5.25% | 4.50% | 5.61% | |
Selling, General and Administrative Expense of Revenue |
— | 34.14% | 23.33% | 24.88% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.06 | 0.06 | |
Share Based Compensation of Revenue |
— | 7.32% | 6.10% | 6.77% | |
Graham Net Nets |
— | (0.91) | (0.66) | (0.67) | |
Graham Number |
— | 3.79 | 4.45 | 9.27 | |
Earnings Yield |
— | (22.58%) | (18.48%) | (29.93%) | |
Free Cash Flow Yield |
— | 23.81% | 7.41% | 8.29% | |
Revenue per Share |
— | 0.62 | 0.91 | 0.67 | |
Operating CF per Share |
— | 0.13 | (0.06) | 0.18 | |
Capex per Share |
— | (0.03) | (0.01) | (0.02) | |
Free Cash Flow per Share |
— | 0.10 | (0.07) | 0.16 | |
Cash per Share |
0.00 | 0.55 | 0.46 | 0.61 | |
Shareholders Equity per Share |
0.00 | 0.55 | 0.43 | (0.59) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.55 | 0.43 | (0.59) | |
Free Cash Flow |
— | 3.58 | (2.70) | 6.03 | |
Working Capital |
58.72 | 57.14 | 62.05 | 62.64 | |
Capital Expenditures |
— | (1.12) | (0.51) | (0.91) | |
Net Current Asset Value |
(115.82) | (127.08) | (129.72) | (165.90) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.05 | 0.02 | 0.04 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
26.83 | 24.06 | 27.60 | 22.91 | |
Average Payables |
6.81 | 7.62 | 8.82 | 9.35 | |
Average Inventory |
31.84 | 30.22 | 29.64 | 30.75 | |
Average Assets |
234.94 | 232.42 | 232.35 | 231.75 | |
Average Common Equity |
(5.99) | (13.55) | (22.32) | (41.97) |
Columns are period end dates · fundamentals updated 6 Nov 2026